GSK
GSK
799 hedge funds and large institutions have $10.5B invested in GSK in 2018 Q4 according to their latest regulatory filings, with 113 funds opening new positions, 222 increasing their positions, 310 reducing their positions, and 92 closing their positions.
40% more call options, than puts
Call options by funds: $118M | Put options by funds: $84.2M
23% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 92
13% more funds holding in top 10
Funds holding in top 10: 15 → 17 (+2)
2% more funds holding
Funds holding: 787 → 799 (+12)
0.03% more ownership
Funds ownership: 4.42% → 4.45% (+0.03%)
5% less capital invested
Capital invested by funds: $11B → $10.5B (-$507M)
28% less repeat investments, than reductions
Existing positions increased: 222 | Existing positions reduced: 310
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$120M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$78.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$68.3M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$67.5M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$67.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$121M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$58.3M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$49.8M |
| 4 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$42.1M |
| 5 |
Morgan Stanley
New York
|
-$41M |
GSK Hedge Fund Activity: Q4 2018 in Review
799 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2018, worth a combined $10.5B — down 4.6% from $11B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new GSK positions and 92 closed out — a net gain of 21 holders — while 222 added to existing stakes and 310 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $120M. The largest seller was Royal Bank of Canada, cutting an estimated $121M.
- 799 institutional investors held GSK (GSK) as of Q4 2018, up from 787 in Q3 2018.
- Funds reported $10.5B of GSK stock for Q4 2018, down 4.6% quarter-over-quarter.
- 113 funds opened new GSK positions in Q4 2018 and 92 closed out, a net change of +21 holders.
- The largest GSK buyer in Q4 2018 was Arrowstreet Capital, an estimated $120M added.
- The largest GSK seller in Q4 2018 was Royal Bank of Canada, an estimated $121M sold.
Based on aggregated 13F filings for Q4 2018.